                                                                                                                            Research article

     Lysosomal disruption preferentially targets
    acute myeloid leukemia cells progenitors
        Mahadeo  Sukhai,1 Swayam Prabha,1 Rose Hurren,1 Angela C. Rutledge,1 Anna Y. Lee,2
       Shrivani Sriskanthadevan,1 Hong Sun,1 Xiaoming Wang,1 Marko Skrtic,1 Ayesh Seneviratne,1
           Maria Cusimano,1 Bozhena Jhas,1 Marcela Gronda,1 Neil MacLean,1 Eunice E. Cho,1
      Paul  Spagnuolo,1 Sumaiya Sharmeen,1 Marinella Gebbia,2 Malene Urbanus,2 Kolja Eppert,1
             Dilan Dissanayake,3 Alexia Jonet,4 Alexandra Dassonville-Klimpt,4 Xiaoming Li,1
            Alessandro Datti,5,6 Pamela S. Ohashi,3 Jeff Wrana,5 Ian Rogers,5 Pascal Sonnet,4
          William Y. Ellis,7 Seth J. Corey,8 Connie Eaves,9 Mark D. Minden,1 Jean C.Y. Wang,1,10
                   John E. Dick,1 Corey Nislow,2 Guri Giaever,2 Aaron D. Schimmer1
                         1Princess Margaret Hospital Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
          2Department  Molecular Genetics, Donnelly Centre Cellular Biomolecular Research, University Toronto, Toronto, Ontario, Canada.
                 3Campbell Family Institute Breast Cancer Research, Toronto, Ontario, Canada. 4Laboratoire des Glucides, CNRS FRE 3517,

             UFR Pharmacie, UniversitÃ© Picardie Jules Verne, 1, Amiens, France. 5Samuel Lunenfeld Research Institute, Mount Sinai Hospital,
                Toronto, Ontario, Canada. 6Department Experimental Medicine Biochemical Sciences, University Perugia, Perugia, Italy.
                     7Department Chemical Informatics, Division Experimental Therapeutics, Walter Reed Army Institute Research,

        Silver Spring, Maryland, USA. 8Departments Pediatrics Cell Molecular Biology, Northwestern University Feinberg School Medicine,
                      Chicago, Illinois, USA. 9Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
                                           10Department Medicine, University Toronto, Toronto, Ontario, Canada.




    Despite efforts understand treat acute myeloid leukemia (AML), remains need com-
    prehensive therapies prevent AML-associated relapses. identify new therapeutic strategies AML,
    screened library  patent drugs identified antimalarial agent mefloquine com-
    pound selectively kills AML cells AML stem cells panel leukemia cell lines mice. Using
    yeast genome-wide functional screen mefloquine sensitizers, identified genes associated     yeast vacuole, homolog mammalian lysosome. Consistent  determined mefloquine
    disrupts lysosomes, directly permeabilizes lysosome membrane, releases cathepsins cytosol.
    Knockdown lysosomal membrane proteins LAMP1 LAMP2 resulted decreased cell viability,     did treatment AML cells known lysosome disrupters. Highlighting potential therapeutic rationale
    strategy, leukemic cells significantly larger lysosomes compared normal cells, leukemia-
    initiating cells overexpressed lysosomal biogenesis genes. results demonstrate lysosomal disruption
    preferentially targets AML cells AML progenitor cells, providing rationale testing lysosomal disrup-
    tion novel therapeutic strategy AML.

Introduction                                                                            previously reported, impact disrupting lysosomes Despite advances understanding aspects                            fully elucidated. Lysosomes acidic organelles, typi-
molecular basis treatment human acute myeloid leukemia                           cally 50â€“100 nm diameter, produced Golgi appara-
(AML), relapse rates remain high (1). factor account                       tus. sequester hydrolases, lipases, proteases (10â€“12) clinical problems presence leukemia-initiating                      control protein degradation, cholesterol biosynthesis, cells (LICs) bulk AML population (2, 3) resis-                      organelle recycling. Unregulated release lysosomal hydrolases
tant conventional chemotherapy agents. suggests                        proteases cytosol triggers caspase-independent cell
identification therapeutic strategies target AML com-                       death (13â€“17).  report antileukemic effects partments sparing normal hematopoietic cells impor-                       lysosome disruption derive increased lysosomal size tant order improve outcomes AML patients.                                  biogenesis AML.
  therapeutic strategy target cellâ€™s protein degrada-
tion machinery. 26S proteasome, lysosome,                            Results
constitutes cellâ€™s protein degradation/recycling machin-                            Identification antimalarial mefloquine initial screen ery (4â€“6). biological role proteasome                          compounds cytotoxic leukemic cells vitro. identify known com-
described, proteasome inhibitors used clinically                            pounds antileukemic activity, compiled library 100 treatment multiple myeloma mantle cell lymphoma                               patent drugs, focusing antimicrobials meta-
(7â€“9). utility targeting proteasome                           bolic regulators wide therapeutic windows. screened
                                                                                        library dose-response manner (72-hour incubation) Authorship note: Mahadeo  Sukhai Swayam Prabha contributed equally             panel leukemia cell lines measured cell growth viabil- work.                                                                              ity using MTS assay. Previously reported treatment
Conflict  authors declared conflict exists.    leukemia cells ivermectin, potent compound
Citation article: J Clin Invest. 2013;123(1):315â€“328. doi:10.1172/JCI64180.    identified screen (18).

	                                    Journal Clinical Investigationâ€‚â€‚â€‚ http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 1â€‚â€‚â€‚January 2013	                   315
 research article




Figure 1
Mefloquine exhibits cytotoxicity AML cells vitro.   High-throughput screen 100 known drugs  represented diamond) OCI-
AML2 leukemia cells, ranked EC50 value. (B) (R)- (S)-mefloquine. (C) Effect mefloquine treatment (24 hours) mouse monocyte-derived
dendritic cells, mouse bone marrow mononuclear cells, MDAY-D2 mouse leukemia cells. Data represent mean percent viability Â± SD
(Annexin V/PI staining) compared vehicle-treated controls 3 independent experiments. (D) Effect mefloquine treatment (left panel,
30 hours; right panel, 48 hours) viability (Annexin V/PI staining) normal human hematopoietic cells (n = 9) primary human AML samples
(n = 17). EC50 values sample, calculated using median effect method  Methods). *P < 0.05; **P < 0.01; ***P < 0.005. bracket
indicates comparison mefloquine sensitive AML normal samples. Line indicates comparison AML normal samples.
(E) Effect mefloquine treatment (10 Î¼M) colony forming potential normal human hematopoietic samples (n = 3) primary human AML
cells (n = 4). Data represent mean percent inhibition colony formation Â± SD compared untreated cells. (F) Effect mefloquine pre-
treatment (10 Î¼M, 24 hours) engraftment normal leukemic cells. Data represent percent engraftment human CD45+CD33+
cells mouse femurs. data point represents single mouse.


  Mefloquine second active drug identified, based              (EC50 31.8 Â± 5.4 Î¼M) murine monocyte-derived normal den-
ranking drug EC50s (Figure 1, B). Subsequent testing            dritic cells (EC50 17. 6 Â± 2.7 Î¼M) (Figure 1C). Quinoline-derived
effect mefloquine 10 human mouse leukemia                     compounds induce differentiation (19, 20), mefloquine
cell lines showed 8 10, mefloquine reduced growth                recently reported induce differentiation human pluripo-
viability EC50s 8 Î¼M (Table 1). Mefloquine-induced               tent stem cells (21).  mefloquine did induce differen-
cell death confirmed Annexin V propidium iodide                      tiation TEX leukemia cells (Supplemental Figure 1B).
(PI) staining, cell death increased prolonged incuba-                    Mefloquine kills primary human AML cells effectively normal
tion drug (Supplemental Figure 1A; supplemental mate-                  human hematopoietic cells. compared ability meflo-
rial available online article; doi:10.1172/JCI64180DS1).              quine kill cells primary human AML samples (Supplemen- contrast effects leukemia cells, mefloquine               tal Table 1) normal human hematopoietic cells, following 30
cytotoxic normal murine bone marrow mononuclear cells                        48 hours exposure culture (n = 9 AML, n = 5 normal 
316	                          Journal Clinical Investigationâ€‚â€‚â€‚ http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 1â€‚â€‚â€‚January 2013
                                                                                                                                        research article

    Table 1                                                                         Supplemental Figure 2, B). assays, higher EOBA
    Mefloquine sensitivity panel leukemia cell lines                       values indicate greater synergy drug combination.                                                                                     18 compounds diverse therapeutic classes diverse
    Cell line	              EC50 (Î¼M)	               95  CI                         mechanisms action.  strikingly, 10  including
    HL60	     4.02	2.58â€“6.25                                                        artemisinin class antimalarials (27, 28), proved com-
    MDAY-D2	 4.23	3.41â€“5.05                                                         pounds known increase production ROS.     KG1A	     5.00	4.80â€“5.21                                                        6 reported effect ROS, remaining 2     OCI-AML2	5.59	3.99â€“7.84                                                         reported increase ROS production (refs. 29â€“34 Table 2).
    TEX	      5.79	4.36â€“7.58                                                          assessed effects mefloquine ROS genera-
    NB4	      6.04	5.37â€“6.78                                                        tion TEX OCI-AML2 cells. hour treatment
    K562	     7.85	6.26â€“9.85
                                                                                    mefloquine increased ROS production concentrations     OCI-M2	 7.94	7.54â€“8.37
                                                                                    induced cell death previous experiments (Figure 2A). Increased
    U937	     9.17	4.97â€“16.89
    THP1	    11.40	7.12â€“18.26                                                       ROS production observed primary AML patient sam-
                                                                                    ples sensitive mefloquine-induced cell death,     EC50 95  CI values calculated cell growth viability           AML cells insensitive mefloquine     data 3 independent experiments, using median-effect method.            normal hematopoietic cells (Figure 2B Supplemental Figure
                                                                                    2C). evaluated ROS production using combination                                                                                     mefloquine artemisinin class antimalarials, 30 hours; n = 11 AML, n = 6 normal 48 hours). Mefloquine                     synergistic combinations screen. Consistent pre-
preferentially cytotoxic primary AML cells, compared                    vious reports (35), artesunate artenimol increased ROS pro-
normal hematopoietic cells (Figure 1D Supplemental Figure                       duction TEX OCI-AML2 cells (Supplemental Figure 2D).
1, C D). addition, mefloquine preferentially cytotoxic                   Synergistic combinations mefloquine artenimol artesu- AML progenitor cells, compared normal hematopoietic                         nate synergistically increased ROS production (Figure 2C).
progenitors (Supplemental Figure 1E). observed AML                       treatment ROS scavenger Î±-tocopherol, known cell lines (Supplemental Figure 1A), longer exposures increased                     inhibit lysosomal lipid-mediated ROS production (36), inhibited toxicity mefloquine AML (Supplemental Figure 1C)                     ROS production (Supplemental Figure 2E) abrogated meflo- normal cells, selectivity AML cells continued                 quine-induced cell death (Figure 2D) doses mefloquine manifest (Figure 1D Supplemental Figure 1D). subgroup                      led >50  cell death. Conversely, N-acetyl-l-cysteine (NAC), AML samples appeared particularly sensitive mefloquine,                      ROS scavenger acts inhibition thiol redoxâ€“medi- obviously associated differences cytogenetic                   ated ROS production (36), effect ROS cell viability
risk overt clinical characteristics (Supplemental Table 1).                mefloquine treatment (Supplemental Figure 2E Figure
   assessed effects mefloquine functionally                       2D). data suggested mefloquine-mediated ROS defined subsets primitive human AML normal cell pop-                         associated changes lysosomal stability.
ulations, using established assays (2, 3, 22). Pre-treatment mefloquine reduced subsequent clonogenic growth primary
human AML cells, effect clonogenic growth                           Table 2 normal human hematopoietic cells (Figure 1E). Pre-treatment                          List compounds synergistic mefloquine mefloquine reduced ability primary human AML
cells repopulate marrow NOD/SCID mice following                               Drug             Synergy 	 ROS 	               Ref.
intrafemoral transplantation (Figure 1F). contrast,                         	                      score	producer?
pre-treatment protocol did alter repopulating activity                      Artenimol	               21.42	 Yes	 Supplemental Figure 2C
normal cord blood cells (Figure 1F).  mefloquine effectively                      Saqinavir base	          18.33	 Yes	         37
targets populations leukemic cells, including LICs,                    Artemisinin	             18.17	Yes	          38
reduced toxicity normal hematopoietic cells.                                        Artesunate	              13.49	 Yes	 Supplemental Figure 2C
   combinatorial high-throughput screen identifies mefloquine inducer          Saquinavir 	             13.41	 Yes	         37
                                                                                       â€ƒmesylate ROS. Mefloquine currently used treatment prophy-
                                                                                       Clotrimazole	            11.43                    36
laxis malaria (23, 24), mechanism action antima-                   Rifabutin	               10.58	 reported	
larial fully elucidated. determine mechanism                       Manidipine 	              9.98	 reported	
underlying toxic effect mefloquine AML cells,                         â€ƒdihydrochloride
formed combination chemical screen, reasoning compounds                         Lopinavir	               9.76	Yes	                   37 synergize mefloquine induce common cell death                          Ritonavir	               8.73	Yes	                   37
pathways. screen, chose TEX leukemia cells (25),                     Amantadine HC1	          5.45	                    35 derived overexpressing TLS-ERG oncogene primary                         Rifaximin	               4.89	 reported	
cord blood cells. Accordingly, treated aliquots TEX cells                   Acetylspiramycin	        4.30	 reported	
increasing concentrations mefloquine combination                            Tiamulin hydrogen 	      3.94	     Yes	              34
                                                                                       â€ƒfumarate
increasing concentrations expanded library patent                                                                                        Atazanavir	              3.18	Yes	                   37 patent drugs (n = 552). screen, identified vali-                  Colistin sulphate	       2.93	 reported	
dated 18 compounds synergized mefloquine defined                          Imatinib mesylate	       2.53	     Yes	              33 excess Bliss additivism (EOBA; ref. 26) statistic greater                   Vandetanib	              2.14	 reported	 2 SDs mean library drugs (ref. 26, Table 2,

	                                Journal Clinical Investigationâ€‚â€‚â€‚ http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 1â€‚â€‚â€‚January 2013	                 317
 research article




Figure 2
Mefloquine synergizes ROS-producing compounds target lysosome.   TEX (left panel) OCI-AML2 (right panel) cells treat-
ed mefloquine (5 10 Î¼M) vehicle control 24 hours ROS levels measured using 5- 6)-carboxy-2â€²7â€²-dichlorodihydrofluorescein
diacetate (carboxy-H2DCFDA) staining. Data represent mean Â± SD fold increase ROS compared vehicle controlâ€“treated cells 3
replicates representative experiment. (B) primary AML samples (left panel: samples 1â€“3 sensitive mefloquine; sample 4 insensitive mefloquine; Supplemental Figure 2B) 2 normal PBSC samples (right panel) treated mefloquine 24 hours ROS levels
measured using carboxy-H2DCFDA staining flow cytometry (*P < 0.05). (C) Heat maps demonstrating induction ROS, measured  TEX leukemia cells treated combinations mefloquine artesunate artenimol, indicated. EOBA score defined Supple-
mental Methods. (D) TEX cells treated mefloquine (8 Î¼M) 48 hours combination ROS scavengers Î±-tocopherol
(3 mM) NAC (10 mM). incubation, cell viability measured Annexin V/PI staining. Data represent mean Â± SD fold increase ROS production compared vehicle controlâ€“treated cells 3 replicates representative experiment  significant protection mefloquine-mediated cell death scavenger treatment: P < 0.05).



  Haploinsufficiency profiling Saccharomyces cerevisiae identifies        protein predicted represent unique mefloquine target, 
yeast vacuole lysosome targets mefloquine. explore      sistent previous observations (37). negative controls, mechanism mefloquineâ€™s antileukemic activity, used hap-                compared mefloquine results antimicrobials known
loinsufficiency profiling (HIP), validated chemical genom-                mechanisms action unrelated lysosome, including tige-
ics platform developed Saccharomyces cerevisiae (37â€“39). HIP              cycline, chloramphenicol, linezolid, flubendazole, clioquinol, assay allows unbiased quantitative measure relative drug               ciclopirox olamine (ref. 41, Supplemental Figure 3, C, Sup-
sensitivity approximately 6,000 yeast proteins single             plemental Tables 4â€“6). compounds showed significant
vivo assay, resulting rank-ordered list likely protein          enrichment mitochondrial function (tigecycline, chlorapheni-
targets, pathways, processes. Gene set enrichment analysis                col, linezolid), SWR1 complex (flubendazole), proteasome
(GSEA; ref. 40) demonstrated gene deletion strains associated               function (clioquinol), regulation cellular pH (ciclopirox sensitivity mefloquine significantly enriched genes              olamine), respectively. vacuole functions involved vacuolar processes, yeast parallel mammalian                enriched clioquinol ciclopirox olamine datasets, lysosome functions (Figure 3A Supplemental Table 3). Spe-                    enrichments significant likely indi-
cifically, significant enrichment vacuolar localization              cate putative secondary effects. Taken  results processing, endosome transport, Golgi vesicle transport                  yeast genomic screen suggest mefloquine specifically targets
(Supplemental Table 3). processes share number genes                  lysosomal function. finding consistent mefloquineâ€™s
(indicated connecting edges Figure 3A), highlighting               known ability preferentially accumulate lysosomes fact processes interrelated. Notably, vacuolar protein            malarial parasite (42).
sorting genes help drive enrichment signifi-                   Mefloquine disrupts AML lysosomes. determine cantly enriched processes  â€œLeading edge genesâ€? column               selective toxicity mefloquine human AML cells medi- processes FDR 0 Supplemental Table 3 ref. 40).                ated lysosome disruption, isolated lysosomes TEX,
Taken  data provide rationale examining                 OCI-AML2, HL-60 cells, cells mefloquine-
effect mefloquine mammalian lysosome.                                  sensitive primary AML patient samples. Purity lysosomal
  case, putative target member tightly               fractions confirmed immunoblotting lysosomal
regulated large complex genes act concert, single              membrane protein LAMP1 mitochondrial protein COX II

318	                           Journal Clinical Investigationâ€‚â€‚â€‚ http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 1â€‚â€‚â€‚January 2013
                                                                                                                                    research article




Figure 3
Mefloquine disrupts lysosomes.   Biological processes protein complexes associated sensitivity mefloquine. node represents process/complex significantly enriched genes associated mefloquine sensitivity (FDR â‰¤ 0.01). Node size proportional signifi-
cance enrichment  e., proportional â€“log10[FDR value]). width edges (represented gray lines diamond) proportional level gene overlap connected categories. Edges shown overlap coefficient 0.5. Node color shows clus-
ter membership, clustering based level overlap categories groups related categories. (B) Cathepsin B
release isolated lysosomes mefloquine treatment (20 Î¼M, 90 minutes). Data represent mean cathepsin B release Â± SD vehicle- mefloquine-treated samples. *P < 0.05, **P < 0.01. (C) Cathepsin L release isolated lysosomes mefloquine treatment (20 Î¼M,
90 minutes). Data represent mean cathepsin L release Â± SD vehicle- mefloquine-treated samples. *P < 0.05, **P < 0.01. (D) Citrate syn-
thase release mitochondria isolated OCI-AML2 cells treated mefloquine. (E) Cathepsin B release lysosomes isolated TEX cells treated tigecycline. Data represent mean cathepsin B release Â± SD. (F) Cathepsin B release lysosomes isolated OCI-AML2 cells treated tigecycline. Data represent mean cathepsin B release Â± SD.

	                            Journal Clinical Investigationâ€‚â€‚â€‚ http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 1â€‚â€‚â€‚January 2013	                319
 research article




Figure 4
Mefloquine disrupts lysosomes leukemia cells.   Left panel: TEM analysis lysosomes TEX cells treated 24 hours mefloquine
(10 Î¼M). Data represent mean percent intact lysosomes Â± SD relative control-treated cells. Middle right panels: Quantification LysoTracker acridine orange uptake TEX cells treated 24 hours mefloquine (10 Î¼M). Results (mean Â± SD 3 replicates representative experi-
ment) represent percent lysosomal integrity relative control cells. (B) Lysosome integrity, measured LysoTracker acridine orange uptake, treatment mefloquine (10 Î¼M) 24 hours cells insensitive (sample 1, EC50 >12 Î¼M) sensitive AML samples (samples 2â€“6, EC50
5â€“8 Î¼M) normal human hematopoietic cells (n = 3). Results (mean Â± SD 3 replicates representative experiment) represent percent
lysosomal integrity relative control cells. *P < 0.05. (C) Cathepsin B release mefloquine (10 Î¼M) treatment shown immunofluorescence
microscopy. Representative fields (Ã—80 objective magnification) shown. Arrow indicates aggregate cathepsin B activity. Scale bars: 5 Î¼m.
(D) TEX cells treated 8 Î¼M mefloquine combination bafilomycin A1 (900 nM) 24 hours, cell viability determined Annexin V/PI. Results (mean Â± SD 3 replicates representative experiment) represent viability compared controls.



(Supplemental Figure 3D), demonstrating                       B, Supplemental Figure 4, E). Likewise, using
5-fold enrichment lysosomal enzyme acid phosphatase.                     immunofluorescence microscopy, cathepsin B
Mefloquine directly disrupted lysosomes isolated AML cell                   present cytoplasm mefloquine-treated AML cells
lines primary AML patientsâ€™ samples, dose-dependent                     large aggregates (Figure 4C), consistent lysosome disrup-
manner, measured release cathepsins B L (Figure 3,                  tion (43â€“45). contrast, unrelated antimicrobials tigecycline,
B C, Supplemental Figure 3E). effects mefloquine                  ivermectin, ciclopirox olamine effect lysosomal specific lysosomes, mefloquine treatment did dis-                 integrity despite ability induce cell death, consistent rupt isolated mitochondria (Figure 3D). Finally, lysosome dis-                   different modes action outcome yeast
ruption general feature cell death, unrelated                genomic screen (refs. 18, 41, 46, Supplemental Figure 4, Fâ€“K).
antimicrobial, tigecycline, did disrupt isolated lysosomes                note, lysosome disruption preceded increased ROS generation
cytotoxic concentrations (Figure 3, E F, ref. 41).                       (Supplemental Figure 4E) inhibited ROS scaven-
  evaluated effects mefloquine integrity                gers (Supplemental Figure 4L). consistent mechanism
lysosomes intact AML cells treated vitro. dose-depen-                 cell death related lysosome disruption finding dent manner, mefloquine disrupted lysosomes TEX leukemia                      mefloquine-mediated cell death independent caspase-3
cells mefloquine-sensitive cells AML patients,                  activation (Supplemental Figure 4M). addition, inhibition normal hematopoietic cells, mefloquine-insensitive primary AML                   lysosomal cathepsins treatment vacuolar ATPase
cells, THP1 cells, early 6 hours treatment.              inhibitor bafilomycin A1 protected mefloquine-mediated
demonstrated transmission electron microscopy (TEM) analy-                    cell death (Figure 4D). contrast, inhibition single cathepsins,
sis staining LysoTracker acridine orange (Figure 4,                  e.g., cathepsin D, insufficient inhibit mefloquine-mediated

320	                           Journal Clinical Investigationâ€‚â€‚â€‚ http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 1â€‚â€‚â€‚January 2013
                                                                                                                                      research article




Figure 5
Characterization mefloquine diastereomersâ€™ effects cell viability lysosome integrity.   Chemical structures mefloquine diastereo-
mers. (B) OCI-AML2 cells treated increasing concentrations indicated mefloquine diastereomer 48 hours. incubation, cell
viability measured MTS. Relative viability calculated comparison vehicle-treated controls. Data represent mean percent
viability Â± SD 3 replicates representative experiment. (C) OCI-AML2 cells treated increasing concentrations indicated
mefloquine diastereomer 24 hours. incubation, lysosome integrity measured LysoTracker staining flow cytometry. Relative
lysosome integrity calculated comparison vehicle-treated control cells. Data represent mean percent lysosome integrity Â± SD 3 replicates representative experiment.


cell death (Supplemental Figure 4N), consistent mefloquine                   (Figure 5B) lysosome disruption intact cells (Figure 5C).
releasing multiple cathepsins cytosol. Taken                    (â€“) (+)-erythro forms mefloquine potent data point mefloquine-mediated lysosomal disruption                   threo forms assays (Figure 5, B C, Sup- cellular mechanism underlying antileukemic action.                            plemental Figure 5, B). note, clinical-grade mefloquine,
  Effects mefloquine enantiomers analogs lysosome integrity         commercial supply, contain little threo
cell viability. Mefloquine racemic mixture 4 diastereomers                forms (refs. 47, 48, data shown). examined (Figure 5A).  assessed effects (â€“) (+)-eryth-             efficacy 6 compounds structurally related mefloquine ro threo forms mefloqine viability leukemia cells                previously shown antimalarial activity (Supple-

	                              Journal Clinical Investigationâ€‚â€‚â€‚ http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 1â€‚â€‚â€‚January 2013	                   321
 research article




Figure 6
Genetic chemical strategies disrupt lysosomes antileukemia effects.   Left: Mean Â± SD change LAMP1 mRNA compared untransduced controls shRNA-mediated knockdown LAMP1 (*P < 0.05). Right: LAMP1 actin protein expression shRNA-mediat-
ed knockdown. Molecular weights (kDa) indicated. (B) Left: Mean Â± SD change LAMP2 mRNA compared untransduced controls shRNA-mediated knockdown LAMP2 (*P < 0.05). Right: LAMP2 protein expression isolated lysosomes shRNA-mediated knockdown.
Molecular weights (kDa) indicated. Asterisk indicates nonspecific band. Equal protein loading confirmed Ponceau S staining. (C) Num-
ber viable OCI-AML2 cells trypan blue staining shRNA-mediated knockdown LAMP1, LAMP2, control sequences. Data represent
mean Â± SD number viable cells 4 replicates representative experiment. (D) Mean Â± SD lysosome integrity (acridine orange staining),
ROS production (carboxy-H2DCFDA staining), sensitivity 8 Î¼M mefloquine (MTS assay) shRNA-mediated knockdown LAMP1.
Mean Â± SD lysosome integrity (24 hours, LysoTracker staining) (E) viability (48 hours, Annexin V staining) (F) OCI-AML2 cells treated LeuLeuOMe. (G) Mean Â± SD lysosome integrity (LysoTracker staining) TEX cells treated 16 hours 5 Î¼M artesunate artenimol. (H)
Mean Â± SD percent inhibition clonogenic growth primary AML normal hematopoietic cells pretreated 5 Î¼M artesunate 48 hours plated clonogenic growth assays (*P < 0.05).

322	                          Journal Clinical Investigationâ€‚â€‚â€‚ http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 1â€‚â€‚â€‚January 2013
                                                                                                                                    research article




Figure 7
AML cells increased lysosomal mass compared normal hematopoietic cells.   Lysosome size (nm2) number quantified TEM AML cells primary AML normal samples. Data represent mean Â± SEM (left panel) (*P < 0.05; **P < 0.01; ***P < 0.001). arrow
indicates CD34+ AML sample. (B) Ordered heat maps illustrating expression lysosome biogenesis genes functionally defined bulk AML
cells (CD34+ cells 6 samples, CD34â€“CD38+ cells 12 samples, CD34â€“CD38â€“ cells 11 samples) versus normal CD34+ cord
bloodâ€“derived HSCs (n = 3 samples). Data derived dataset GSE30377, archived GEO database. Genes rank ordered fold change significance. (C) Ordered heat maps illustrating expression subset lysosome biogenesis genes functionally defined
LIC-enriched cell populations (CD34+CD38â€“ cells 13 samples CD34+CD38+ cells 6 samples, indicated) versus HSCs (n = 3
samples). indicated upregulated downregulated, respectively. (D) Expression lysosomal cathepsins functionally defined
bulk AML cells  B) versus normal CD34+ cord bloodâ€“derived HSCs (n = 3 samples). (E) Expression lysosomal cathepsins functionally
defined LIC-enriched cell populations  C) versus HSCs (n = 3 samples).

	                            Journal Clinical Investigationâ€‚â€‚â€‚ http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 1â€‚â€‚â€‚January 2013	                323
 research article

                                                                                Figure 8
                                                                                Increased cathepsin B enzymatic activity LysoTracker uptake dis-
                                                                                tinguish mefloquine-sensitive mefloquine-insensitive primary AML
                                                                                patient samples.   Cell extracts normal CD34+ cells primary
                                                                                (1) AML samples (n = 5) treated 0.2  Triton X disrupt                                                                                 lysosomal membranes. cathepsin B substrate 1 mM Arg-Arg-
                                                                                7-amido-4-methylcoumarin hydrochloride (1 mM) added incu-
                                                                                bated 1 hour 37Â°C. resulting fluorescence measured.
                                                                                Data represent mean fold change cathepsin B release Â± SD,
                                                                                compared normal sample (set 1.00); ***P < 0.001. Arrows
                                                                                indicate CD34+ AML samples. (B) Relative lysosomal mass normal
                                                                                hematopoietic cells (n = 3 samples), primary AML cells insensitive                                                                                 mefloquine (EC50 >15 Î¼M; n = 3), primary AML cells sensitive                                                                                 mefloquine (EC50 <8 Î¼M; n = 5) measured using LysoTracker
                                                                                staining flow cytometry. Data represent mean relative increase
                                                                                LysoTracker uptake 3 replicates single sample. Arrows indi-
                                                                                cate CD34+ AML samples.


                                                                                isolated lysosomes, increased ROS production,                                                                                 reduced viability TEX OCI-AML2 leukemia cell lines
                                                                                (Figure 6, Eâ€“G, Supplemental Figure 9B; compare Sup-
                                                                                plemental Figure 2, D, Supplemental Figure 9A). THP1
                                                                                U937 cells sensitive LeuLeuOMe-mediated lysosome
                                                                                disruption cell death (Supplemental Figure 7, E F,                                                                                 Supplemental Figure 8, E F), suggesting mechanism                                                                                 lysosome-mediated cell death different mefloquine.
                                                                                Furthermore, artesunate preferentially reduced clonogenic
                                                                                growth primary AML cells compared normal hematopoi-
                                                                                etic cells (Figure 6H). Overall, results genetic chemi-
mental Table 7 ref. 49). compounds induced cell               cal experiments validate lysosomal disruption novel plau-
death disrupted lysosomes leukemia cells concentrations                sible therapeutic strategy AML. 15 Î¼M (Supplemental Figure 5, C D).                                     Lysosome size increased AML. investigate basis   Lysosome disruption therapeutic strategy leukemia.         differential sensitivity leukemic cells normal hematopoi-
explore potential antileukemic effect lysosomal disrup-                  etic cells lysosomal disruption, assessed characteristics tion, asked genetic strategies mimic effects               lysosomes types cells. TEM revealed lysosomes
obtained mefloquine. LAMP1 LAMP2 predomi-                      larger primary human AML cells, including CD34+ AML
nant lysosomal membrane proteins function,  main-                cells, AML cell lines, comparison lysosomes
tain integrity lysosomal membrane malignant cells                 normal human CD34+ hematopoietic cells (Figure 7A
(10â€“12, 50, 51). asked lentiviral vectorâ€“mediated               Supplemental Figure 10A). larger size, num-
shRNA knockdown LAMP1 LAMP2 target leu-                       ber lysosomes cell did differ significantly AML
kemic cells. Effective knockdown gene transcripts                   normal cells (Figure 7A).
proteins confirmed quantitative real-time RT-PCR                       Additionally, confirmed previously reported
immunoblotting, using independent shRNAs gene                      lysosomal biogenesis signature genes (54), cathepsin
(Figure 6, B). Compared control, shRNA knockdown                     mRNA, overexpressed primary bulk human AML cells, LAMP1, lesser extent LAMP2, reduced growth                  CD34+CD38â€“ CD34+CD38+ subsets enriched viability OCI-AML2 leukemia cells (Figure 6C). LAMP1                     LICs, compared primitive phenotype normal
knockdown associated decreased lysosome integrity,                     human hematopoietic cells (refs. 55â€“57, Figure 7, Bâ€“E, Sup-
increased ROS production, decreased cell viability, increased               plemental Figure 10, Bâ€“D). Taken  results indi-
sensitivity mefloquine (Figure 6D). Similar effects LAMP1                 cate mechanism explain observed differential
knockdown lysosome integrity cell viability observed                activity lysosome disruption leukemic normal human TEX leukemia cells (Supplemental Figure 6).  THP1                   hematopoietic cells.
U937 cells, sensitive mefloquine treatment                     Finally, mefloquine-sensitive primary AML cells, including
(Table 1 Supplemental Figure 4D), exhibited lesser effects               CD34+ human AML cells, higher cathepsin B enzymatic activ-
lysosome integrity cell proliferation LAMP1 knockdown,                ity compared insensitive AML cells normal hematopoiet-
compared OCI-AML2 cells (Supplemental Figure 7, D,                   ic cells (P < 0.001; Figure 8A). Likewise, uptake LysoTracker
Supplemental Figure 8, D).                                                    dye significantly higher mefloquine-sensitive primary AML
  test lysosome-based mechanism action,                 cells, including CD34+ subset  compared treated leukemia cell lines l-leucine-leucine-methyl ester                 normal CD34+ hematopoietic cells cells mefloquine-
(LeuLeuOMe), artesunate, artenimol, report-                insensitive AML samples (P < 0.01; Figure 8B).  differ-
ed disrupt lysosomes added intact cells (35, 52, 53).                ences help identify subsets AML patients likely
Treatment agents disrupted lysosomes intact cells                 respond lysosome disrupters.

324	                          Journal Clinical Investigationâ€‚â€‚â€‚ http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 1â€‚â€‚â€‚January 2013
                                                                                                                                     research article




Figure 9
Mefloquine demonstrates therapeutic efficacy AML cells growing vivo. Sublethally irradiated SCID mice injected subcutaneously  B) OCI-AML2 (C) K562 human leukemia cells (D) MDAY-D2 mouse leukemia cells. tumors palpable, mice treated 50 mg/kg mefloquine vehicle control daily oral gavage (n = 10 condition). Tumor weight measured time sacrifice. (E)
Lysosome integrity (LysoTracker staining) single-cell suspensions derived control mefloquine-treated OCI-AML2â€“derived tumors
generated xenografted mice. (F) Primary AML samples (2 Ã— 106 cells) injected intrafemorally sublethally irradiated NOD/SCID mice
(n = 20) allowed repopulate mice 2.5 weeks, described Methods. period, mice (n = 10 treatment condition) treated 100 mg/kg/d oral gavage additional 4.5 weeks sacrificed. Bone marrow non-injected femurs collected;
stained anti-human antibodies cell surface markers CD45, CD33, CD19; analyzed flow cytometry. Data represent percent
CD45+ CD33+ CD19â€“ human AML cells present non-injected femurs. Serum bilirubin (G), alkaline phosphatase (H), aspartate transaminase  ,
creatine kinase (J), creatinine (K), mouse body weight (L) vehicle- mefloquine-treated mice (50 mg/kg Ã— 21 days)  serum markers liver kidney function, n = 3 treatment condition; body weight, n = 6 controls n = 5 mefloquine-treated mice).



  Mefloquine demonstrates antitumor activity leukemic cells growing           exhibited lysosomal disruption, consistent vitro xenografted mice. Given antileukemic activity displayed                findings (Figure 9E).
mefloquine vitro, evaluated effect oral meflo-                   transplanted sublethally irradiated NOD/SCID mice
quine mouse human leukemia cells growing trans-                        intrafemorally primary human AML cells later evaluated
planted immunodeficient mice. Mouse MDAY-D2 cells                            effects 4.5-week course mefloquine starting 2.5 weeks
human OCI-AML2 K562 cells transplanted subcutane-                        transplantation (10 mice group). Mefloquine treatment
ously NOD/SCID mice treatment started 7 days later                      significantly reduced level leukemic cells compared tumors palpable (10 mice group). Com-                      control mice assessed end treat-
pared vehicle control, mefloquine reduced tumor growth                      ment period (Figure 9F), evidence toxicity (body weight, 3 models (Figure 9, D). Mefloquine-responsive tumors                    appearance, behavior mice) noted.

	                             Journal Clinical Investigationâ€‚â€‚â€‚ http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 1â€‚â€‚â€‚January 2013	                325
 research article

  evaluate greater potential effects mefloquine              results agreement prior reports showing normal tissues dose produced antileukemic                 increased cathepsin expression (67) lysosomal mass (50)
effects, treated untreated SCID mice meflo-                  oncogene-mediated transformation. Prior studies indi-
quine 21 days. effects body weight, appearance,                   cated increased lysosomal biogenesis lead increases
behavior confirmed, gross changes               lysosomal volume (54). addition, Ono et al. (68) previously organs necropsy histologic evaluation (Supplemental               suggested increased lysosomal volume render cells
Figure 11). alterations serum levels liver         sensitive death lysosome disruption blue light
muscle/cardiac enzymes, alterations renal func-              irradiation, mechanism unclear. 
tion (Figure 9, Gâ€“L, Supplemental Figure 12).  vivo,               ings taken report provide strong
mefloquine disrupts lysosomes inhibits vivo growth               rationale therapeutically targeting lysosome AML, leukemia cells significant toxicity normal host tissues.            larger lysosomes sensitive disruption.                                                                                support idea comes results indicating Discussion                                                                     cells mefloquine-sensitive AML samples signifi- report mefloquine, quinoline approved                   cantly increased lysosomal mass, measured LysoTracker dye
treatment prevention malaria (23, 24), toxicity                 uptake, compared cells mefloquine-insensitive
human AML cells including AML progenitors, sparing                   samples normal hematopoietic sources.  increased lyso-
mal human hematopoietic cells treated doses. Fur-                somal size mass predictive biomarker sensitivity thermore, antileukemic effects mefloquine              lysosomal disruption human AML.
mediated disruption lysosomes, previously unappre-                  Currently, unclear AML cells increased lysosom-
ciated mechanism action drug.                                       al mass biogenesis. Given role lysosomes macro-
   treatment mild-moderate Plasmodium falciparum malaria,            molecule organelle recycling, function increase
patients receive single oral dose 1,250 mg mefloquine,              levels amino acids nucleotides necessary cell prolifer- usually sufficient eradicate parasite (24).            ation.  recent report indicated intracellular levels regions mefloquine-resistant malaria prevalent, patients           amino acids regulate expression TFEB, transcrip- received higher doses, 25 mg/kg, drug signifi-           tion factor responsible activation lysosomal biogenesis toxicity (58). addition, serum concentrations mefloquine            pathways (54, 69â€“71). addition, increased lysosomal mass 5 Î¼M reported individuals receiving 250 mg                  AML necessary provide source fatty acids weekly malaria prophylaxis (59, 60).  antileukemia                cells. Recently, demonstrated AML cells centrations mefloquine pharmacologically achievable.                 higher reliance fatty acids energy supply, AML
   mefloquine known accumulate lysosomes                 cells primitive elements increased rates of malarial parasite (42), mechanism action anti-             fatty acid oxidation (72).
malarial unclear.  work inform                  summary, combined approach using small-molecule mechanism action mefloquine malaria,               yeast mutant screens vitro vivo functional studies
selectively disrupt lysosomes malarial parasite.              AML identified lysosome disruption novel prom- demonstrated mefloquine disrupts lysosomes                     ising therapeutic strategy human AML. Investigation yeast study strongly suggests intact lysosome required              mechanistic basis selective sensitivity primary human resistance mefloquine, future studies identify direct            AML cells agents disrupt lysosomes revealed increased
binding target(s) lysosomes leukemia cells possibly              lysosomal size biogenesis bulk AML cells subsets malarial vacuole major                                 enriched AML stem cells.  spite genetic    Autophagy lysosome-mediated process cellular autodi-                biological heterogeneity AML, common biological fea-
gestion  times nutrient deprivation, enables cell            tures remain accessible selective targeting potential
recycle raw materials macromolecular organellar biosyn-                therapeutic exploitation.
thesis. inhibiting promoting autophagy lead cell
death cancer (ref. 61 reviewed ref. 62). antimalarial            Methods
chloroquine structurally similar mefloquine inhibits                 Detailed experimental procedures available Supplemental Methods degradation autophagy targets autophagolysosome.                 Supplemental Table 2. mechanism, chloroquine induce cell death                    Primary cells. Fresh peripheral blood samples obtained 
sensitize cells chemotherapy (including imatinib mesylate                senting AML patients mononuclear cells fractionated Ficoll sep-
chronic myeloid leukemia; refs. 63â€“66) radiation.               aration. Similarly, primary normal hematopoietic mononuclear cells involves induction lysosome disruption, mechanism                 obtained healthy consenting volunteers donating mobilized periph-
action mefloquine appears distinct chloroquine                 eral blood stem cells (PBSCs) transplantation allogeneic recipients. inhibitors autophagy.                                             Primary cells cultured 37Â°C 5  CO2 IMDM supplemented
   LAMP1 LAMP2 predominant proteins lyso-                   10  FBS appropriate antibiotics.
somal membrane, accounting approximately 50  pro-                     Assessment anticancer activity mouse models leukemia. MDAY-D2 mouse
tein mass contained (14â€“16). Previous studies dem-                leukemia cells human K562 OCI-AML2 leukemia cells (2.5 Ã— 105)
onstrated knockdown LAMP1 LAMP2 disrupts                        injected subcutaneously flanks sublethally irradiated
integrity lysosomes malignant cells non-trans-                (3.5 Gy) NOD/SCID mice (Ontario Cancer Institute, Toronto, Ontario,
formed cells (50). Consistent finding, observed              Canada). (OCI-AML2), 5 (MDAY-D2), 7 (K562) days injec-
knockdown LAMP proteins decreases proliferation leu-                 tion, tumors palpable, mice treated mefloquine
kemic cells, decreases lysosome integrity.                            (50 mg/kg/d) oral gavage water vehicle control (n = 10 group).

326	                         Journal Clinical Investigationâ€‚â€‚â€‚ http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 1â€‚â€‚â€‚January 2013
                                                                                                                                                         research article

Tumor volume (tumor length Ã— width2 Ã— 0.5236) measured 3 times                          Study approval. collection use human tissue study week using calipers. Fourteen (MDAY-D2), 15 (OCI-AML2), 17 (K562)                        approved University Health Network, Mount Sinai Hospital, days injection cells, mice sacrificed, tumors excised,                University British Columbia institutional review boards. samples
volume mass tumors measured.                                                     obtained donors provided written informed consent.   assess mefloquine mouse models primary AML cord bloodâ€“                       animal studies carried according regulations Cana-
derived HSC engraftment, frozen aliquot AML cells cord blood cells                  dian Council Animal Care approval Ontario Cancer thawed counted. Cord bloodâ€“derived HSCs purified using                         Institute animal ethics review board.
antiâ€“human CD34 antibody (Human CD34 Selection Kit, Stemcell Tech-
nologies). Cells resuspended PBS, 1 Ã— 106 2 Ã— 106 viable                     Acknowledgments
trypan blueâ€“negative cells injected marrow right femur                 thank Jill Flewelling administrative assistance help 10-week-old female NOD/SCID mice irradiated 24 hours                       preparation manuscript. work supported previously 208 cGy 137Cs source. mice injected                    Leukemia Lymphoma Society, International Myeloma 200 Î¼g antiâ€“mouse CD122. half weeks injection                   Foundation, Canadian Stem Cell Network, Ontario Insti-
human AML cells, mice treated mefloquine (100 mg/kg p.                       tute Cancer Research funding Ontario Min-
injection) daily vehicle control (n = 10 group) 4.5 weeks.              istry Research Innovation, Ministry Health Mice sacrificed, cells flushed femurs.                      Long-Term Care Province Ontario, Canadian Insti-
Engraftment human AML marrow assessed enumer-                            tutes Health Research (CIHR), Terry Fox Foundation.
ating percentage human CD45+CD33+CD19â€“ cells flow cytom-                          M  Sukhai CIHR Post-Doctoral Fellow Ontario Min-
etry using BD FACSCalibur flow cytometer. Data analyzed                       istry Research Innovation Post-Doctoral Fellow. G. Giaever
FlowJo version 8.8 (TreeStar).                                                              C. Nislow supported grant National Human
  Statistics. Statistical tests conducted, unless indicated,                 Genome Research Institute (NHGRI) grant Cana-
using GraphPad Prism version 4 (GraphPad Software) Microsoft                            dian Cancer Society   020380). D. Schimmer Leukemia
Excel. statistical comparisons cell culture assays, 2-tailed Stu-                  Lymphoma Society Scholar Clinical Research.
dentâ€™s t test (2-population) 1-way ANOVA (multi-population) applied appropriate. statistical comparisons data derived                    Received publication April 10, 2012, accepted revised
animal studies human patient samples, Mann-Whitney U test                        form October 4, 2012.
applied 2-population comparisons, Kruskal-Wallis test, Dunns post-test, applied 3-population comparisons. Signifi-                     Address correspondence  Aaron D. Schimmer, Princess Mar-
cance cutoffs P < 0.05 applied instances. Drug EC50s                    garet Hospital, Rm 9-516, 610 University Ave, Toronto, Ontario,
calculated using median effect method (33), CalcuSyn ver-                      Canada M5G 2M9. Phone: 416.946.2838; Fax: 416.946.6546;
sion 2.0 software package (Biosoft).                                                        E-mail: aaron.schimmer@utoronto.ca.
	 1.	Lowenberg B, et al. Mitoxantrone versus daunoru-             2010;376(9758):2075â€“2085.                                 	 21.	Sachlos E, et al. Identification drugs including      bicin induction-consolidation chemotherapy â€”        	10.	Bagshaw RD, Mahuran DJ, Callahan JW. pro-                      dopamine receptor antagonist selectively tar-
     value low-dose cytarabine maintenance             teomic analysis lysosomal integral membrane                  cancer stem cells. Cell. 2012;149(6):1284â€“1297.
     remission, assessment prognostic fac-           proteins reveals diverse composition           	 22.	Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Tar-
     tors acute myeloid leukemia elderly: final         organelle. Mol Cell Proteomics. 2005;4(2):133â€“143.              geting CD44 eradicates human acute myeloid leu-
     report. European Organization Research         	11.	Bagshaw RD, Mahuran DJ, Callahan JW. Lyso-                       kemic stem cells. Nat Med. 2006;12(10):1167â€“1174.
     Treatment Cancer Dutch-Belgian                somal membrane proteomics biogenesis               	 23.	Boudreau E, et al. Tolerability prophylactic Lari-
     Hemato-Oncology Cooperative Hovon Group.                     lysosomes. Mol Neurobiol. 2005;32(1):27â€“41.                     regimens. Trop Med Parasitol. 1993;44(3):257â€“265.
     J Clin Oncol. 1998;16(3):872â€“881.                      	 12.	Callahan JW, Bagshaw RD, Mahuran DJ. inte-            	24.	Harinasuta T, Bunnag D, Wernsdorfer WH. 	 2.	Bonnet D, Dick JE. Human acute myeloid leuke-                gral membrane lysosomes: proteins              phase II clinical trial mefloquine patients      mia organized hierarchy originates              roles disease. J Proteomics. 2009;72(1):23â€“33.               chloroquine-resistant falciparum malaria Thai-
     primitive hematopoietic cell. Nat Med. 1997;    	 13.	Brunk UT, Neuzil J, Eaton JW. Lysosomal involve-                land. Bull World Health Organ. 1983;61(2):299â€“305.
     3(7):730â€“737.                                                ment apoptosis. Redox Rep. 2001;6(2):91â€“97.            	25.	Warner JK, et al. Direct evidence cooperating
	 3.	Lapidot T, et al. cell initiating human acute        	14.	Guicciardi  Leist M, Gores GJ. Lysosomes                   genetic events leukemic transformation      myeloid leukaemia transplantation SCID            cell death. Oncogene. 2004;23(16):2881â€“2890.                    normal human hematopoietic cells. Leukemia. 2005;
     mice. Nature. 1994;367(6464):645â€“648.                  	15.	Leist M, Jaattela M. Triggering apoptosis                  19(10):1794â€“1805.
	 4. Duve C. lysosome turns fifty. Nat Cell Biol.          cathepsins. Cell Death Differ. 2001;8(4):324â€“326.         	 26.	Borisy AA, et al. Systematic discovery multicom-
     2005;7(9):847â€“849.                                     	16.	Leist M, Jaattela M. deaths funeral:                  ponent therapeutics. Proc Natl Acad Sci U S  2003;
	 5.	Kroemer G, Jaattela M. Lysosomes autoph-                 caspases alternative mechanisms. Nat Rev                100(13):7977â€“7982.
     agy cell death control. Nat Rev Cancer. 2005;             Mol Cell Biol. 2001;2(8):589â€“598.                         	 27.	Chawira  Warhurst DC, Robinson BL, Peters
     5(11):886â€“897.                                         	 17.	Turk B, et al. Apoptotic pathways: involvement lyso-         W. effect combinations qinghaosu (arte-
	 6.	Luzio JP, Pryor PR, Bright NA. Lysosomes: fusion         somal proteases. Biol Chem. 2002;383(7â€“8):1035â€“1044.            misinin) standard antimalarial drugs      function. Nat Rev Mol Cell Biol. 2007;8(8):622â€“632.    	 18.	Sharmeen S, et al. antiparasitic agent ivermec-             suppressive treatment malaria mice. Trans R
	 7.	Baiocchi RA, et al. Phase 2 trial rituximab           tin induces chloride-dependent membrane hyper-                  Soc Trop Med Hyg. 1987;81(4):554â€“558.
     bortezomib patients relapsed refractory           polarization cell death leukemia cells. Blood.     	28.	Klayman DL. Qinghaosu (artemisinin):      mantle cell follicular lymphoma. Cancer. 2011;           2010;116(18):3593â€“3603.                                         antimalarial drug China. Science. 1985;
     117(11):2442â€“2451.                                     	19.	Iyamu E, Perdew H, Woods G. Growth inhibi-                       228(4703):1049â€“1055.
	 8.	Belch  et al. phase II study bortezomib            tory differentiation effects chloroquine           	 29.	Chang SP, Shen SC, Lee WR, Yang LL, Chen YC. Ima-
     mantle cell lymphoma: National Cancer Insti-             analogue human leukemic cells poten-                 tinib mesylate induction ROS-dependent apop-
     tute Canada Clinical Trials Group trial IND.150.          tiate fetal hemoglobin production targeting                  tosis melanoma B16F0 cells. J Dermatol Sci. 2011;
     Ann Oncol. 2007;18(1):116â€“121.                               polyamine pathway. Biochem Pharmacol. 2009;                 62(3):183â€“191.
	 9.	Cavo M, et al. Bortezomib thalidomide plus              77(6):1021â€“1028.                                          	30.	Hoebe KH, Monshouwer M, Witkamp RF, Fink-
     dexamethasone compared thalidomide plus           	20.	Martirosyan AR, Rahim-Bata R, Freeman AB,                        Gremmels J, van Miert  Cocultures porcine
     dexamethasone induction therapy                Clarke CD, Howard RL, Strobl JS. Differentiation-               hepatocytes Kupffer cells improved
     consolidation therapy  double autologous               inducing quinolines experimental breast cancer               vitro model study hepatotoxic com-
     stem-cell transplantation newly diagnosed mul-            agents MCF-7 human breast cancer cell                    pounds. Vet Q. 2000;22(1):21â€“25.
     tiple myeloma: randomised phase 3 study. Lancet.           model. Biochem Pharmacol. 2004;68(9):1729â€“1738.           	 31.	Nakamura T, Lipton SA. Preventing Ca2+-mediat-


	                                    Journal Clinical Investigationâ€‚â€‚â€‚ http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 1â€‚â€‚â€‚January 2013	                                           327
 research article

      ed nitrosative stress neurodegenerative diseases:           target tumor cells attack mitochondria                treatment uncomplicated falciparum
      possible pharmacological strategies. Cell Calcium.             processing bid leading Necroptosis. J Immunol.             malaria Rondonia, Brazil. Braz J Infect Dis. 2006;
      2010;47(2):190â€“197.                                            2009;182(11):6993â€“7000.                                          10(4):279â€“282.
	32.	Thapa D, et al. Inhibitory effects clotrimazole        	46.	Eberhard Y, et al. Chelation intracellular iron          	 59.	Charles BG, et al. Population pharmacokinetics       TNF-alpha-induced adhesion molecule expres-                 antifungal agent ciclopirox olamine                     mefloquine military personnel prophylaxis
      sion angiogenesis. Arch Pharm Res. 2009;                   induces cell death leukemia myeloma cells.                malaria infection field deployment.
      32(4):593â€“603.                                                 Blood. 2009;114(14):3064â€“3073.                                   Eur J Clin Pharmacol. 2007;63(3):271â€“278.
	 33.	Touzet O, Philips  Resveratrol protects        	 47.	Karle JM, Olmeda R, Gerena L, Milhous WK. Plas-            	 60.	Nevin RL. Pharmacokinetic considerations       protease inhibitor-induced reactive oxygen species             modium falciparum: role absolute stereochem-                  repositioning mefloquine treatment pro-
      production, reticulum stress lipid raft pertur-            istry antimalarial activity synthetic amino            gressive multifocal leukoencephalopathy. Clin Neu-
      bation. AIDS. 2010;24(10):1437â€“1447.                           alcohol antimalarial agents. Exp Parasitol. 1993;                rol Neurosurg. 2012;114(8):1204â€“1205.
	34.	Zhang S, Chen H, Gerhard GS. Heme synthesis                     76(4):345â€“351.                                             	 61.	Hu YL, et al. Hypoxia-induced autophagy promotes
      increases artemisinin-induced radical formation          	 48.	Wallen L, Ericsson O, Wikstrom  Hellgren U. High-              tumor cell survival adaptation antiangio-
      cytotoxicity suppressed superox-            performance liquid chromatographic method                        genic treatment glioblastoma. Cancer Res. 2012;
      ide scavengers. Chem Biol Interact. 2010;186(1):30â€“35.         enantioselective analysis mefloquine               72(7):1773â€“1783.
	35.	Hamacher-Brady  et al. Artesunate activates                   plasma urine. J Chromatogr B Biomed Appl. 1994;        	 62.	Yang ZJ, Chee CE, Huang S, Sinicrope FA. role
      mitochondrial apoptosis breast cancer cells             655(1):153â€“157.                                                  autophagy cancer: therapeutic implications.
      iron-catalyzed lysosomal reactive oxygen species         	 49.	Mullie C, Jonet  Desgrouas C, Taudon N, Sonnet                 Mol Cancer Ther. 2011;10(9):1533â€“1541.
      production. J Biol Chem. 2010;286(8):6587â€“6601.                P. Differences anti-malarial activity 4-amino-       	 63.	Bellodi C, et al. Targeting autophagy potentiates
	 36.	Wu SJ, Ng LT, Lin CC. Effects vitamin E              alcohol quinoline enantiomers investigation                  tyrosine kinase inhibitor-induced cell death       cinnamaldehyde-induced apoptotic mechanism                  presumed underlying mechanism action.                  Philadelphia chromosome-positive cells, includ-
      human PLC/PRF/5 cells. Clin Exp Pharmacol Physiol.             Malar J. 2012;11:65.                                             ing primary CML stem cells. J Clin Invest. 2009;
      2004;31(11):770â€“776.                                     	 50.	Fehrenbacher N, et al. Sensitization lysosom-             119(5):1109â€“1123.
	 37.	Giaever G, et al. Chemogenomic profiling: iden-                al cell death pathway oncogene-induced             	 64.	Ding WX, et al. Oncogenic transformation confers
      tifying functional interactions small mol-              regulation lysosome-associated membrane pro-                  selective susceptibility combined suppres-
      ecules yeast. Proc Natl Acad Sci U S  2004;               teins 1 2. Cancer Res. 2008;68(16):6623â€“6633.                sion proteasome autophagy. Mol Cancer
      101(3):793â€“798.                                          	 51.	Huynh KK, Eskelinen EL, Scott CC, Malevanets                   Ther. 2009;8(7):2036â€“2045.
	 38.	Giaever G, et al. Genomic profiling drug sensitivi-         Saftig P, Grinstein S. LAMP protein